Outcome of Board Meeting Dated 11.02.2025

The Board of Medi-Caps Limited approved its unaudited financial results for Q3 FY26 (quarter ended 31 Dec 2025) along with nine-month results. On a standalone basis, the company swung back to a profit of Rs 28.50 lakhs in Q3 (vs Rs 26.47 lakhs a year ago) and posted a 9-month PAT of Rs 17.42 lakhs compared to a loss of Rs 15.10 lakhs last year; standalone nine-month revenue rose ~37% to Rs 177.06 lakhs. On a consolidated basis, however, nine-month revenue fell sharply by about 51% to Rs 899.71 lakhs and the company slipped into a much wider loss of Rs 607.93 lakhs (vs Rs 228.92 lakhs loss last year). The major drag came from wholly-owned subsidiary Medgel Private Limited, which posted a loss after tax of Rs 625.35 lakhs. The company operates two segments – Pharma (main contributor at Rs 722.67 lakhs in 9M FY26) and Real Estate (Rs 177.24 lakhs, largely from shop sales at Medi-caps Business Park). Auditor Rawka & Associates issued an unmodified limited review opinion on both sets of results.